Participated · Series B · Jun 2026

Oblenio Bio is advancing LBL-051, a tri-specific T-cell engager that unites BCMA, CD19 and CD3 and is specifically engineered for autoimmune patients. Preclinical data presented at EULAR 2026 showed complete depletion of peripheral and tissue B cells and plasma cells with step-up dosing, emergence of immature non-memory B cells upon recovery, dose-dependent decreases in peripheral immunoglobulins, and no observed cytokine release syndrome in non-human primates. The company is moving rapidly toward clinical development and plans to initiate a first-in-human proof-of-concept study this year. Oblenio holds an exclusive option from Leads Biolabs for a global license to develop, manufacture, and commercialize LBL-051. Its leadership team includes CEO Samantha Truex, and the board will include representatives from Pfizer Ventures, Deep Track Capital, and Aditum Bio following the Series B. Oblenio is based in Cambridge, Mass., and has just completed a $62 million Series B to fund its clinical program.

Participated · Series B · Mar 2025

Tempero Bio is a clinical-stage biopharmaceutical company advancing TMP-301, a next-generation mGluR5 negative allosteric modulator (NAM) designed to prevent relapse by targeting the biology of addiction. TMP-301 has shown promising results in preclinical models of alcohol, cocaine and opiate use disorders and has been evaluated in over 80 healthy volunteers in Phase 1 with an acceptable safety and tolerability profile and robust PET-measured receptor occupancy. The company has initiated a Phase 2 trial in alcohol use disorder and a drug–drug interaction study in people using cocaine, with a Phase 2 cocaine trial planned following the DDI study. Tempero plans to use new financing to support two Phase 2 clinical trials, Phase 3-enabling activities, and additional preclinical studies and formulation work. The company is focused on addressing large unmet needs—there are no FDA-approved medications for cocaine use disorder and high prevalence of alcohol and drug use disorders drives demand for new therapies. Tempero Bio is an Aditum Bio portfolio company and recently announced John Wagner, M.D., Ph.D., will join as Chief Medical Officer.

Participated · Seed · Jun 2024

Qeen.ai builds autonomous AI agents for e-commerce that handle content creation, marketing, and conversational sales for merchants across MENA. Its platform uses proprietary RL-UI technology to continuously learn from consumer interactions and dynamically personalize content (for example, device-specific text formats). Since launching its Dynamic Content agent in Q2 2024, Qeen says it has served over 15 million users, generated 1 million SKU descriptions, and helped merchants increase sales by 30%; notable clients include Dubai Store, 6th Street, and Jumia. The company employs a subscription-based, value-driven pricing model: content automation is charged per active SKU (typically $0.10–$0.20 per SKU per month) while its AI marketing agent is priced by interaction; Qeen declined to disclose total customers or revenue growth. Founded by former Google and DeepMind engineers Morteza Ibrahimi (CEO), Ahmad Khwlieh (CTO), and Dina Alsamhan (CBO), Qeen currently has over 25 employees across the UAE and Jordan and plans to scale across MENA before expanding globally. The startup is using new funding to expand its AI platform, grow the team, and attract more customers amid rapid regional e-commerce growth. qeen.ai is a Dubai-based AI startup founded in 2023 by Dina Alsamhan, Ahmad Khwileh and Morteza Ibrahimi. The company provides no-code, native GenAI product-discovery solutions for e-commerce businesses of all sizes. Its platform learns from user interactions and autonomously improves content in real time and across multiple languages without manual intervention. qeen.ai aims to boost online sales and customer lifetime value (LTV) for its clients. The company closed a $2.2M Pre-Seed funding round and intends to use the proceeds to expand operations and its business reach. Investors in the round include Wamda Capital, 10x Founders, Aditum, Dara Holdings, Jabbar Group, Phaze Ventures and Eureka 460.

Participated · Series A · Feb 2022

Hubpay operates a cross-border digital wallet aimed at driving financial inclusion across MENAP by offering zero-cost domestic and international remittances. The company leverages transaction volumes and data to build bespoke financial products and has multiple products in the pipeline, including financing and insurance solutions for remittance receivers. Hubpay was founded in September 2019 and maintains offices in Dubai, Abu Dhabi, Karachi and London. It was the first startup to obtain a full Category 3c license in the UAE in 2020 and holds In Principle Approval for an EMI license in Pakistan. The company says it will use the Series A proceeds to grow the team and expand internationally, with planned expansion across Asia and Africa in 2022. Hubpay positions its mission around financial inclusion and aligns product development with relevant UN Sustainable Development Goals.

Led · Series A · Sep 2021

Via Nova Therapeutics is an Oakland, Calif.-based company established to discover and develop therapeutics for acute and subacute viral infections. Founded by virologists Don Ganem, MD, and Kelly Wong, PhD, the company in-licensed four preclinical antiviral programs from Novartis. Its programs target fundamental mechanisms of viral replication and aim to produce therapies for respiratory viruses including influenza, adenoviruses and rhinoviruses, as well as human polyomaviruses that cause severe disease in immunocompromised hosts. The focus on core replication mechanisms also positions the company to support discovery of therapeutics for other viral infections. Via Nova closed a $20 million Series A financing. The company will use the funds to advance the four in-licensed preclinical programs toward further development.